These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 24115369)

  • 21. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dapagliflozin: a review of its use in type 2 diabetes mellitus.
    Plosker GL
    Drugs; 2012 Dec; 72(17):2289-312. PubMed ID: 23170914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.
    Kaku K; Kiyosue A; Inoue S; Ueda N; Tokudome T; Yang J; Langkilde AM
    Diabetes Obes Metab; 2014 Nov; 16(11):1102-10. PubMed ID: 24909293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
    Puckrin R; Saltiel MP; Reynier P; Azoulay L; Yu OHY; Filion KB
    Acta Diabetol; 2018 May; 55(5):503-514. PubMed ID: 29484489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis.
    Yang XP; Lai D; Zhong XY; Shen HP; Huang YL
    Eur J Clin Pharmacol; 2014 Oct; 70(10):1149-58. PubMed ID: 25124541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
    Del Prato S; Nauck M; Durán-Garcia S; Maffei L; Rohwedder K; Theuerkauf A; Parikh S
    Diabetes Obes Metab; 2015 Jun; 17(6):581-590. PubMed ID: 25735400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Zheng Z; He D; Chen J; Xie X; Lu Y; Wu B; Jiang X
    Clin Drug Investig; 2023 Apr; 43(4):209-225. PubMed ID: 37010676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
    Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
    Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
    Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
    Albarrán OG; Ampudia-Blasco FJ
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of novel sodium glucose cotransporter-2 inhibitor remogliflozin in the management of type 2 diabetes mellitus: A systematic review and meta-analysis.
    Dutta D; Jindal R; Mehta D; Khandelwal D; Sharma M
    Diabetes Metab Syndr; 2021; 15(6):102315. PubMed ID: 34700292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time.
    Parikh S; Wilding J; Jabbour S; Hardy E
    Int J Clin Pract; 2015 Feb; 69(2):186-98. PubMed ID: 25438821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z; Sun J; Han R; Fan D; Dong X; Luan Z; Xiang R; Zhao M; Yang J
    Diabetes Obes Metab; 2018 Jan; 20(1):113-120. PubMed ID: 28656707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin.
    Nauck MA; Del Prato S; Durán-García S; Rohwedder K; Langkilde AM; Sugg J; Parikh SJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1111-20. PubMed ID: 24919526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.
    Zhong X; Lai D; Ye Y; Yang X; Yu B; Huang Y
    Eur J Clin Pharmacol; 2016 Jun; 72(6):655-63. PubMed ID: 26832915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
    Kleefstra N; Drion I; van Hateren KJ; Holleman F; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2013; 157(38):A5969. PubMed ID: 24050445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.